%0 Journal Article
%T A Phase II Trial of Osimertinib in the Second-Line Treatment of Non-small Cell Lung Cancer with the EGFR T790M Mutation, Detected from Circulating Tumor DNA: LiquidLung-O-Cohort 2
%A Cheol-Kyu Park
%A Hyun-Ju Cho
%A In-Jae Oh
%A Yoo-Duk Choi
%A Young-Chul Kim
%J Archive of "Cancer Research and Treatment : Official Journal of Korean Cancer Association".
%D 2019
%R 10.4143/crt.2018.387
%K Osimertinib
%K T790M
%K Circulating tumor DNA
%K Non-small cell lung carcinoma
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6473264/